The available ICI drug classes include CTLA-4 inhibitors, PD-1/PD-L1 inhibitors, CTLA-4/PD-1 inhibitor combinations, and CTLA-4/LAG3 inhibitor combinations, with the response to these therapies being highly influenced by the type of cancer. This evidence concerns the gene CTLA4 and cancer.